Jump Financial, LLC Bei Gene, Ltd. Transaction History

Jump Financial, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Oct 21, 2024	BUY	$158.67 - $201.58 $38,239 - $48,580	241 Added 14.01%	1,961 $353,000
Q4 2023 Feb 07, 2024	BUY	$158.67 - $201.58 $311,151 - $395,298	1,961 New	1,961 $353,000
Q2 2023 Oct 21, 2024	BUY	$178.3 - $266.78 $306,676 - $458,861	1,720 New	1,720 $306,000
Q2 2023 Aug 07, 2023	BUY	$178.3 - $266.78 $306,676 - $458,861	1,720 New	1,720 $306,000
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $236,661 - $346,964	-908 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $200,949 - $287,481	908 New	908 $235,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.